1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited

0.01
AUD
0.00
(0.00%)
-0.03EPS
51.95MMarket Cap
Mar 03Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
Basic EPS, GAAP
-0.03
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
- -
-0.01
-0.01
-0.01
-0.05
-0.03
Free Cash Flow per Basic Share
-0.03
-0.01
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.01
0.01
0.01
0.02
- -
0.02
0.02
0.01
0.02
0.06
0.04
0.02
Tangible Book Value per Share
0.03
0.01
0.01
0.01
0.02
- -
0.02
0.02
- -
0.01
0.04
0.03
0.01
Basic Weighted Avg Shares
41
86
158
434
488
760
936
973
976
1,154
1,502
1,845
2,165
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
6
34
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12,431.05
-2,568.82
-1,499.72
-205.05
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
Net Income, GAAP
-1
-1
-2
-5
-11
-17
-17
-3
-13
-9
-14
-86
-70
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8,893.05
-2,304.63
-1,500.65
-206.41
Working Capital
2
1
3
5
16
- -
23
21
7
12
79
75
49
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23
11
Total Equity
2
1
3
5
16
1
24
21
8
23
109
81
64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-58.43
-77.48
-110.77
-101.39
-201.65
-137.97
-15.01
-90.98
-58.86
-21.07
-90.93
-96.35

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
435.17%
89.48%
-21.87%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
110.27%
163.94%
-19.25%
Sales/Revenue/Turnover
- -
- -
487.11%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
6
2026
- -
- -
34

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.05
2026
- -
- -
-0.03

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Howie McKibbon
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Tower 5, Collins Square West Perth VIC Australia 3008
IPO Date
Jul 12, 2004
Website
botanixpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Botanix Pharmaceuticals Limited (ASX: BOT) is a clinical-stage dermatology company developing and commercializing antimicrobial skin products based on its proprietary patented cannabidiol (CBD) platform technology. The company offers a pipeline of product candidates including BTX 170, a non-antibiotic treatment for serious skin infections such as atopic dermatitis and hidradenitis suppurativa; Sofdra, a cannabidiol cream for the treatment of primary axillary hyperhidrosis; and additional formulations targeting acne vulgaris, psoriasis, and other inflammatory skin diseases. Botanix manufactures and sells pharmaceutical products focused on dermatological applications, with operations primarily in Australia and the United States. Founded in 2014 and headquartered in Sydney, Australia, the company targets the global dermatology market, serving patients with inflammatory and infectious skin conditions through partnerships with contract manufacturers and clinical trial networks across North America and Europe. Its business segments encompass research and development, clinical trials, regulatory approvals, and commercialization of CBD-based topical therapies. In the last two years, Botanix has advanced its pipeline with positive Phase 3 trial results for Sofdra in 2024, leading to a New Drug Application submission to the U.S. FDA in early 2025; formed a strategic manufacturing alliance with a leading U.S. contract development organization for commercial-scale production; and completed a A$50 million capital raise in late 2024 to fund Phase 2 trials for BTX 170 and market expansion into Europe. The company also acquired complementary IP assets in antimicrobial peptides in mid-2025, enhancing its non-antibiotic platform, and announced leadership expansions to support U.S. commercialization efforts. These developments position Botanix for potential revenue generation from Sofdra approval expected in 2026.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis Transcript

  • seekingalpha.com

    Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Sofdra Update Transcript

  • seekingalpha.com

    Botanix Pharmaceuticals Limited (BXPHF) Q2 2026 Earnings Call Transcript

  • defenseworld.net

    Botanix Pharmaceuticals Q2 Earnings Call Highlights